Holen Sie sich die Stockscreener-App
78.25
5.30%
-4.38
Schlusskurs vom Vortag:
$82.63
Offen:
$77.09
24-Stunden-Volumen:
1.02M
Relative Volume:
3.06
Marktkapitalisierung:
$1.78B
Einnahmen:
$923.71M
Nettoeinkommen (Verlust:
$84.68M
KGV:
19.85
EPS:
3.9419
Netto-Cashflow:
$182.81M
1W Leistung:
-1.20%
1M Leistung:
-9.00%
6M Leistung:
-4.39%
1J Leistung:
+13.39%
1-Tages-Spanne:
$74.33
$78.59
1-Wochen-Bereich:
$74.33
$83.21
52-Wochen-Spanne:
$70.15
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(609) 759-1810
Adresse
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Compare ANIP vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
78.25 | 1.78B | 923.71M | 84.68M | 182.81M | 3.9419 |
TAK
Takeda Pharmaceutical Co Adr
|
17.45 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.03 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.36 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
72.66 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
538.84 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
ANI Pharmaceuticals Inc (ANIP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BlackRock (ANIP) discloses 2.9M-share, 12.8% stake in ANI Pharmaceuticals - Stock Titan
ANI Pharmaceuticals Inc (ANIP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ANI Pharmaceuticals Inc (ANIP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ANI Pharmaceuticals Inc (ANIP) Cash Flow - TradingKey
TradingKey - TradingKey
ANI Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ANIP - TradingView
ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo! Finance Canada
Is ANI Pharmaceuticals (ANIP) A Bargain Following Its Positive SYNCHRONICITY Trial Results? - Yahoo Finance
ANI Pharmaceuticals Inc (ANIP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ANI Pharmaceuticals, Inc. (ANIP) Stock Price, News, Quote & History - Yahoo! Finance Canada
ANIP|ANI Pharmaceuticals Inc|Price:77.650|Chg%:-0.880 - TradingKey
ANIP|ANI Pharmaceuticals Inc|Price:78.370|Chg%:+0.720 - TradingKey
ANI Pharmaceuticals Inc (ANIP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ANI Pharmaceuticals Inc (ANIP) Valuation: PE, PB & Fair Value Analysis - TradingKey
ANI Pharmaceuticals Inc (ANIP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ANI Pharmaceuticals to report Q2 2026 earnings on August 7 with webcast discussion. - Pluang
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET - The Manila Times
Three ANI Pharmaceuticals executives will host Aug. 7 results call - Stock Titan
ANI Pharmaceuticals Inc (ANIP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ANIP5868601 Bond Profile — Key Metrics - TradingView
ANI Pharmaceuticals (ANIP) GC has 2,466 shares withheld for taxes on RSU vesting - Stock Titan
US Generic Drug Stocks With Domestic Manufacturing in Focus - Sahm
ANI Pharmaceuticals (ANIP) On Strong ILUVIEN Trial Data Is The Stock A Bargain - Sahm
How Positive SYNCHRONICITY Trial Data for ILUVIEN at ANI Pharmaceuticals (ANIP) Has Changed Its Investment Story - Sahm
Is ANI Pharmaceuticals Inc (ANIP) a Bargain After 3.3% Drop? GF Value Says Undervalued - GuruFocus
ANI PHARMACEUTICALS INC : CANACCORD GENUITY INITIATES COVERAGE WITH HOLD RATING; TARGET PRICE $91 - Bitget
ANI Pharmaceuticals plans appeal after trial court ruling - Investing.com UK
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target? - qz.com
ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook - qz.com
ANI Pharmaceuticals' 2026 Catalysts Include Gout Push and New Generics - qz.com
ANI Pharmaceuticals plans appeal after trial court ruling By Investing.com - Investing.com South Africa
Ani Pharmaceuticals Announces Intent To Appeal Rulings In CG Oncology Matter - TradingView
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter - The Manila Times
ANI Pharmaceuticals to Appeal Delaware Ruling Denying Post-Trial Motions in CG Oncology Asset Dispute - Quiver Quantitative
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run - AOL.com
symbol__ Stock Quote Price and Forecast - CNN
Frontier tech research, news & data - MLQ.ai
Insider Sell: Meredith Cook Sells 500 Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
ANI Pharmaceuticals shares rise on positive eye implant trial amid insider stock sales - Pluang
ANI Pharmaceuticals (ANIP) counsel sells 500 shares under 10b5-1 plan - Stock Titan
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant - Proactive financial news
ANI Pharmaceuticals reports positive uveitis trial results - grafa.com
ANI Pharmaceuticals reports positive phase 4 trial results By Investing.com - Investing.com South Africa
ANI Pharmaceuticals reports positive phase 4 trial results - Investing.com
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis - The Manila Times
ANI Pharmaceuticals Announces Positive Six-Month Topline - GlobeNewswire
ANI Pharmaceuticals reports positive 6-month da... - Pluang
Enterprise value to EBIT forward of ANI Pharmaceuticals, Inc. – BX:BSFA - TradingView
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run - The Motley Fool
ANI Pharmaceuticals (ANIP) Recalls HydrOXYzine Solution, Is The Pullback A Valuation Opportunity? - Sahm
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.65%
8.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):